450 results about "Membrane protein" patented technology

Provided herein are methods and compositions for treating a subject in need thereof comprising administering an effective amount of vesicles with functional transmembrane proteins embedded in the plasma membrane. Also provided herein are methods of restoring gap junctional communication comprising the administration of an effective amount of vesicles.

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding a transmembrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the transmembrane protein gene product in the host. Modifications are possible within the scope of this invention.

The invention belongs to the field of bioengineering and discloses duck flavivirus. The amino acid sequence of an envelope protein E is shown as SEQ ID NO:4 or the homology of the amino acid sequence which is shown as the SEQ ID NO:4 is over 98 percent. The invention also discloses vaccine for preventing duck flavivirus, and a kit for detecting duck flavivirus; a new virus of duck flavivirus disease which causes output reduction and death of laying duck are separated and identified by various detection means, a method for diagnosing duck flavivirus disease is established, the vaccine for duck flavivirus disease is developed, important basis and means are provided for preventing duck flavivirus, and relative duck flavivirus diseases which cause the output reduction and death of laying duck can be prevented and diagnosed by using the vaccine and a diagnostic reagent which are developed by using the virus.

The invention discloses a multi-target chimeric antigen receptor. The multi-target chimeric antigen receptor provided by the invention consists of a main peptide chain and an assistant peptide chain.The main peptide chain includes an antigen binding domain A, an assistant peptide chain connection domain B, a transmembrane domain C and an intracellular signal conduction domain D. The assistant peptide chain includes a main peptide chain connection domain F. The antigen binding domain A is a polypeptide with antigen-bonding function. The assistant peptide chain connection domain B and the mainpeptide chain connection domain F are mutually combined. The transmembrane domain C is the transmembrane domain of arbitrary membrane binding protein or the transmembrane domain of transmembrane protein. The intracellular signal conduction domain D includes a primary signal conduction region. The multi-target chimeric antigen receptor provided by the invention can mediate specific cell killing bycombining two antigen binding domains with different antigens. Also a cytokine and cytokine receptor compound are introduced into the multi-target chimeric antigen receptor provided by the invention and can play the role of cytokines.

Described herein are methods for identifying and preparing bivalent binding molecules to 7 transmembrane G protein-coupled receptors. The methods disclosed herein are based on the SELEX method for generating high affinity nucleic acid ligands. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The methods of this invention combine two or more binding domains to two or more different epitopes of the same 7 transmembrane G protein-coupled receptor. These bivalent binding molecules are useful as therapeutic and diagnostic agents.

CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 23-25, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 26-28, respectively.

The present invention relates in part to amino acid sequences that are directed against and / or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed, Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed. Pharmaceutical composition, recombinant vaccines comprising and live attenuated pathogens are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.

The invention discloses a fully-human-derived monoclonal antibody for neutralizing HCV (hepatitis C virus) and an application thereof and particularly discloses an antibody capable of recognizing and combining HCV envelope protein E2, a coding gene thereof, an expression vector and an application. The monoclonal antibody can stop the HCV from infecting susceptible cells and is fully-human-derived, and the antibody has greatly reduced immunogenicity, good affinity, good treatment effect and low side effects as compared with other animal-derived anti-HCV molecules.

The invention discloses a recombinant African swine fever virus CD2V subunit protein as well as a preparation method and application thereof. The protein comprises an extracellular region and an intracellular region of African swine fever virus surface envelope protein, and the amino acid sequence of the protein is shown as SEQ ID NO.3. The preparation method comprises the following steps: 1) cloning a codon-optimized gene sequence shown as SEQ ID NO.1 into an eukaryotic expression vector; 2) transfecting a recombinant expression vector containing the African swine fever virus subunit proteincoding gene into CHO cells; 3) culturing, screening and domesticating a CHO cell strain in the step 2) to obtain a highly-expressed cell strain; 4) fermenting and culturing the cell strain in the step3), and performing purifying to obtain the African swine fever virus CD2V subunit protein; and 5) mixing the CD2V protein with a pharmaceutically acceptable adjuvant to obtain a subunit vaccine. Theinvention can provide the African swine fever surface CD2V subunit protein which can be industrially produced on a large scale, the preparation method is simple and low in cost, and the prepared vaccine can reach the existing national standard.